Asceneuron

Asceneuron, founded in 2012 and headquartered in Lausanne, Switzerland, discovers and develops innovative small molecules to halt and prevent key molecular events in the brain that lead to neurodegeneration. Asceneuron strives to address high unmet medical needs in neurodegenerative diseases such as orphan tauopathies, Alzheimer’s, and Parkinson’s diseases.